On June 24, 2025, Avidity Biosciences, alongside Dr. Nicholas Johnson, presented the much‑anticipated topline results from the FORTITUDE Phase 1/2 study of del‑brax (also known as delpacibart braxlosiran), during an FSHD University … Continue reading Breaking Down Avidity’s FORTITUDE Phase 1/2 Trial Update